Retail investors are now looking forward to a full approval of Anktiva in the EU for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
IBRX Stokes Retail Chatter — Investors See Anktiva Beat Merck’s Keytruda With Approval In EU